Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
This activity will cover key topics of interest to stakeholders who set practice policy and will be called upon to evaluate and make decisions on issues pertaining to biosimilars.
Choose from the criteria below to find an activity that fits you best.
|A product of the National Association of Specialty Pharmacy's (NASP) Center for Specialty Pharmacy Education (CSPE)|
NOTE: If you attended the live CE activity titled "Newest Oncology Agents: PD-1 Inhibitors - Clinical Information and Patient Management" that was held on October 1, 2015 during the NASP Annual Meeting & Expo in National Harbor, Maryland AND received CE credit (i.e. a pharmacist CE statement with ACPE Universal Activity Number 0221-9999-15-241-L01-P), you are NOT allowed to also receive CE credit for this home-study activity.
This is a featured CE activity on the Center for Specialty Pharmacy Education (CSPE) website. CSPE is the educational hub of the National Association of Specialty Pharmacy (NASP). Most CSPE activities include the pathophysiology and clinical therapeutics of various disease states in which specialty pharmacy products and services are provided. CSPE also covers legal, regulatory and operational topics relevant to specialty pharmacy practice.
Oncology agents continue to dominate new product developments in specialty pharmacy practice. PD-1s are the newest agents and are expected to have significant impact on patient care. The clinical data for these products is relatively new to the literature, and many went through an accelerated approval process with the FDA; therefore, it is imperative that providers stay on top of the latest information regarding dosing, administration, adverse effects, monitoring, and patient outcomes.
The target audience for this activity is pharmacists. Upon completion of this activity, participants will be able to:
Megan Brafford, PharmD, BCOP
Clinical Oncology Pharmacy Specialist
Baptist Health Lexington
David Kwasny, PharmD, BCOP
Director, Clinical Oncology Services
Onco360 Oncology Pharmacy
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Megan Brafford has no relevant commercial or financial relationships to disclose. David Kwasny has served as a Consultant and/or Speaker for Boehringer-Ingelheim, Incyte, and Seattle Genetics.
The opinions expressed in this activity should not be construed as those of the CE provider. The information and views are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs for unlabeled indications. Use of drugs outside of labeling should be considered experimental and participants are advised to consult prescribing information and professional literature.
Release Date: 04-15-2016
Expiration Date: 04-15-2018
This CE activity is jointly provided by ProCE, Inc. and NASP. ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-16-102-H01-P has been assigned to this knowledge-based home-study CE activity (initial release date 04-15-16). This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. Completion of the evaluation and the post-test with a score of 70% or higher are required to receive CE credit. No partial credit will be given.
No external support has been received for this activity.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.